Demyelinating Disease

The study showed Enyoropathologyekal MS lesions clearly that the process of demyelination occurs in the presence of inflammatory cells and cytokines. Traditionally, demyelination and inflammation MS tie (MS often known as inflammatory demyelinating disease). Research has confirmed recently. Was a significant correlation between the deficit and the clinical onset of permanent nerve cells themselves (especially on the axon)

These insights into the functioning of the immune system led to the development of therapeutic strategies, conducted consisting, for example, prevents management of anti-inflammatory cytokines in patients with MS or treatments that pro-inflammatory cytokines. However, limited ability to predict the effect of such an intervention by the complexity of the network formed by the immune system, with many interrelated factors and mechanisms that vary depending on the stage of the disease. Even more difficult than outside entity heterogeneous MS patients, and that we will see a variety of phenomena such as the masses of the destruction of the cells, and the process of demyelination with or without the participation of the principal cells work as oligodendrogliopathie 'primary.

Given our limited understanding of the pathogenesis of MS, generally or in a particular person, can not be achieved any specific therapeutic progress to be achieved at the expense of clinical trials. These tests are to be carried out on large numbers for a long time, because the path is highly variable and unpredictable disease, and the difficulty in accurately measure neurological disability.